Trial Profile
Interaction of Subcutaneous Lixisenatide 20 microg qd on Pharmacokinetic and Pharmacodynamic Properties of Oral Ramipril 5 mg/day in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2011
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Ramipril
- Indications Cardiovascular disorders; Heart failure; Hypertension; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sanofi
- 20 Jul 2011 New trial record
- 29 Jun 2011 Results presented at the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics.